Atara Biotherapeutics (ATRA) Income towards Parent Company (2013 - 2026)

Atara Biotherapeutics has reported Income towards Parent Company for 14 years, with the latest figure at -$4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 110.91% year-over-year to -$4.1 million; the trailing twelve-month figure through Mar 2026 stood at -$42.2 million (down 169.83% YoY), and the FY2025 full-year result was -$49000.0, up 99.94% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$4.1 million, up from -$36.1 million in the prior quarter.
• The five-year high for Income towards Parent Company was $38.0 million in Q1 2025, with the low at -$88.1 million in Q1 2022.
• Historically, Income towards Parent Company has averaged -$35.0 million across 5 years, with a median of -$31.8 million in 2024.
• Annual changes were most pronounced in 2023 — Income towards Parent Company tumbled 485.08% — and 2025, when it jumped 219.71%.
• Atara Biotherapeutics' Income towards Parent Company stood at -$74.7 million in 2022, then increased by 18.72% to -$60.7 million in 2023, then soared by 79.09% to -$12.7 million in 2024, then slumped by 184.75% to -$36.1 million in 2025, then jumped by 88.53% to -$4.1 million in 2026.
• The last three Income towards Parent Company figures came in at -$4.1 million (Q1 2026), -$36.1 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.